A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

April 1, 2025

Study Completion Date

November 7, 2025

Conditions
RCC, Renal Cell Cancer
Interventions
DIAGNOSTIC_TEST

68Ga-NOTA-RCCB6 PET/CT Scan

"The imaging agent 68Ga-NOTA-RCCB6 used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is between 5.0 and 8.0; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations.~Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection. The maximum mass dose of CD70 should not exceed 240ug, and the maximum volume of administration should not exceed 5 mL."

Trial Locations (1)

710000

RECRUITING

Department ofNuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an, China, Xi'an, China

All Listed Sponsors
lead

Xijing Hospital

OTHER